ATE442592T1 - Detektion und/oder beobachtung von synuclein- assoziierten krankheiten - Google Patents

Detektion und/oder beobachtung von synuclein- assoziierten krankheiten

Info

Publication number
ATE442592T1
ATE442592T1 AT03709934T AT03709934T ATE442592T1 AT E442592 T1 ATE442592 T1 AT E442592T1 AT 03709934 T AT03709934 T AT 03709934T AT 03709934 T AT03709934 T AT 03709934T AT E442592 T1 ATE442592 T1 AT E442592T1
Authority
AT
Austria
Prior art keywords
synuclein
monitoring
detection
patient
associated diseases
Prior art date
Application number
AT03709934T
Other languages
English (en)
Inventor
David Allsop
Omar M A El-Agnaf
Sultan A Salem
Original Assignee
Lancaster University Business
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9931023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lancaster University Business filed Critical Lancaster University Business
Application granted granted Critical
Publication of ATE442592T1 publication Critical patent/ATE442592T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03709934T 2002-02-14 2003-02-14 Detektion und/oder beobachtung von synuclein- assoziierten krankheiten ATE442592T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203446.0A GB0203446D0 (en) 2002-02-14 2002-02-14 Detection and/or monitoring of synuclein-related diseases
PCT/GB2003/000677 WO2003069332A2 (en) 2002-02-14 2003-02-14 Detection and/or monitoring of synuclein-related diseases

Publications (1)

Publication Number Publication Date
ATE442592T1 true ATE442592T1 (de) 2009-09-15

Family

ID=9931023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709934T ATE442592T1 (de) 2002-02-14 2003-02-14 Detektion und/oder beobachtung von synuclein- assoziierten krankheiten

Country Status (9)

Country Link
US (1) US20050176078A1 (de)
EP (1) EP1476758B2 (de)
JP (1) JP2005528588A (de)
AT (1) ATE442592T1 (de)
AU (1) AU2003214364A1 (de)
CA (1) CA2480466C (de)
DE (1) DE60329165D1 (de)
GB (1) GB0203446D0 (de)
WO (1) WO2003069332A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2310057B1 (es) * 2004-07-19 2009-11-17 Oryzon Genomics, S.A. Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy.
CN1752104B (zh) * 2004-09-21 2010-05-05 北京市肿瘤防治研究所 突触蛋白γ的单克隆抗体及其应用
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5558834B2 (ja) * 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
US20120190652A1 (en) * 2009-09-16 2012-07-26 United Arab Emirates University Diagnostic agent for parkinson's disease
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
WO2012061789A2 (en) * 2010-11-05 2012-05-10 Brandeis University Tetrameric alpha-synuclein and use thereof
US9116157B2 (en) * 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
EP2643056A4 (de) * 2010-11-24 2014-06-04 Elan Pharm Inc Phagozytische aktivität als marker für synukleinopathie
MX357193B (es) * 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
US20140295465A1 (en) * 2011-11-02 2014-10-02 Biogen Idec International Neuroscience Gmbh USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
ES2481517B1 (es) * 2013-01-29 2015-06-01 Universidad De Sevilla Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos
JP6980953B2 (ja) * 2014-09-11 2021-12-15 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ミスフォールディングタンパク質の検出
US12265089B2 (en) 2014-09-11 2025-04-01 Board Of Regents Of The University Of Texas System Discriminating Parkinson's disease from multiple system atrophy using alpha-synuclein PMCA
EP3218721B1 (de) 2014-11-14 2021-08-18 United Arab Emirates University Verbindungen zur verwendung als kontrastmittel
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN104711280B (zh) * 2014-12-10 2018-04-13 中国医学科学院医学生物学研究所 表达和纯化同时缺失外显子3和5 的α突触核蛋白选择性剪切体蛋白的方法
CN110869763B (zh) 2017-05-16 2022-07-29 安培里翁公司 错误折叠tau蛋白质的检测
US12521371B2 (en) * 2017-06-19 2026-01-13 Kainos Medicine Inc. Modulators of alpha-synuclein
EP4233901A3 (de) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmazeutische zusammensetzungen mit anti-beta-amyloid-antikörpern
JP7173532B2 (ja) * 2018-08-28 2022-11-16 学校法人順天堂 α－シヌクレイノパチーの診断
RU2703430C1 (ru) * 2018-12-13 2019-10-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия
EP3779448A1 (de) * 2019-08-12 2021-02-17 Baden-Württemberg Stiftung gGmbH Neuartiger diagnostischer marker für die creutzfeldt-jakob-krankheit und morbus-alzheimer
WO2021170659A1 (en) * 2020-02-25 2021-09-02 Markus Otto Diagnosing a disease associated with synaptic degeneration using an elisa for determining a beta-synuclein concentration in csf
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602042A (en) * 1994-04-14 1997-02-11 Cytyc Corporation Method and apparatus for magnetically separating biological particles from a mixture
WO1999050300A1 (en) * 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
AU2001271865C1 (en) * 2000-07-07 2006-12-07 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
WO2002041842A2 (en) * 2000-11-03 2002-05-30 Proteotech. Inc. Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease

Also Published As

Publication number Publication date
CA2480466A1 (en) 2003-08-21
DE60329165D1 (de) 2009-10-22
EP1476758B2 (de) 2015-02-11
EP1476758B1 (de) 2009-09-09
CA2480466C (en) 2010-12-21
JP2005528588A (ja) 2005-09-22
AU2003214364A1 (en) 2003-09-04
WO2003069332A2 (en) 2003-08-21
EP1476758A2 (de) 2004-11-17
US20050176078A1 (en) 2005-08-11
WO2003069332A3 (en) 2004-01-08
GB0203446D0 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
ATE462973T1 (de) Diagnose und prävention der krebszellinvasion
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60108230D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
EP1550462A4 (de) MITTEL ZUR BEHANDLUNG ODER PRûVENTION VON NIERENERKRANKUNGEN UND VERFAHREN ZUR DIAGNOSE VON NIERENERKRANKUNGEN
EP1501531A4 (de) Verfahren zur behandlung von angst und stimmungsstörungen bei älternen personen
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
DE60327530D1 (de) Plasma urotensin und menschliche herzerkrankung
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
ATE552776T1 (de) Verfahren und vorrichtung zur überwachung eines sedierten patienten
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
AU2003272189A8 (en) Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
AU2003299389A8 (en) PRP detection method using an aminoglycoside antibiotic
WO2004019875A3 (en) Non-invasive methods to identify agents for treating pain
ATE410521T1 (de) Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties